中山大学学报（医学科学版）2011，Vol.32Issue(4)：495-499,546,6.
中国人UGT1A128的基因多态性以及与伊立替康毒性和疗效的关系
Association of UGT1A128 Polymorphism with Toxicity and Efficacy of Innotecan in Chinese Patients
摘要
Abstract
[Objective] To observe UGTIAI * 28 genetic polymorphism and the association with the incidence and severity of adverse reaction of irinotecan chemotherapy in Chinese cancer patients with advanced gastrointestinal carcinoma. [Methods] UGTIA1 ★28 genetic polymorphism analysis was performed in 317 patients with cancer from March 2010 to March 2011 in our hospital by amplifying gene fragments using PCR and direct sequencing. Forty-five cases with advanced gastrointestinal cancer treated with irinotecan were observed and recorded the adverse reaction during chemotherapy. The differences of the incidence of grade 3 and 4 adverse reaction were compared in the patients with different genotypes. [Results] Of 317 patients of malignant tumor, 250 cases (78.9%) were identified with (TA) 6/ (TA) 6 genotype, 59 cases (18.6%) were genotyped as heterozygote (TA) 6/ (TA) 7 , and 8 cases (2.5%) were found as (TA) 7/ (TA) 7 genotype. In 44 cases with advanced gastrointestinal cancer treated with irinotecan, 8.6%, 12.5%, and 100% had grade 3 and 4 neutropenia and 14.3%, 12.5%, and 100% had grade 3 and 4 diarrhea, respectively. [Conclusion]The polymorphism of UGTIAI*28 in Chinese patients was low. Patients with (TA) 7/ (TA) 7 genotype treated with irinotecan chemotherapy had increased risk of grade 3 and 4 neutropenia and diarrhea than cases with (TA) 6/ (TA) 7 or (TA) 6/ (TA) 6 genotype. Wild type (TA) 6/ (TA) 6 could be passed screening and how to select the right patients with the appropriate dose of irinotecan in order to improve the efficacy were worthy of further study.关键词
伊立替康；不良反应；疗效；UGT 1A1；基因多态性Key words
Irinotecan/adverse reaction/efficacy/UGT 1A1/genetic polymorphism分类
医药卫生引用本文复制引用
马冬,张绪超,杨冬阳,刘建化,苏健..中国人UGT1A128的基因多态性以及与伊立替康毒性和疗效的关系[J].中山大学学报（医学科学版）,2011,32(4):495-499,546,6.基金项目
广东省科技计划项目(2009B090300277) （2009B090300277）
